EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Evolus, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.96 (+15.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Evolus, Inc. grew revenue 13.9% to $316.49M over the twelve months to Jun 30, 2026. Free cash flow was -$18.28M.
Revenue
$316.49M
+13.9% vs. a year earlier
Operating income
-$18.67M
TTM Q2 2026
Free cash flow
-$18.28M
TTM Q2 2026
EPS, diluted
-$0.52
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $485.24M
- P/E ratio
- –
- Price to sales
- 1.53
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -3.77%
Fundamentals
- Revenue
- $316.49M
- Net income
- -$34.33M
- EPS, diluted
- -$0.52
- Free cash flow
- -$18.28M
- Book value per share
- -$0.47
- Diluted shares
- 66M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$316.49M+13.9% YoY
Gross profit
$211.21M+13.1% YoY
Operating income
-$18.67M
Net income
-$34.33M
EPS, diluted
-$0.52
Free cash flow
-$18.28M
Reported periodTrailing twelve months